Great Lakes Advisors LLC Sells 420,001 Shares of Pfizer Inc. $PFE

Great Lakes Advisors LLC cut its position in Pfizer Inc. (NYSE:PFE) by 60.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 273,489 shares of the biopharmaceutical company’s stock after selling 420,001 shares during the quarter. Great Lakes Advisors LLC’s holdings in Pfizer were worth $6,586,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of PFE. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC purchased a new stake in Pfizer during the second quarter valued at approximately $26,000. HFM Investment Advisors LLC lifted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its stake in Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Finally, Abound Financial LLC purchased a new position in Pfizer in the fourth quarter worth $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Guggenheim lowered their price objective on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Friday, August 7th. Weiss Ratings downgraded Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. decreased their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Trading Up 0.8%

Shares of Pfizer stock opened at $28.00 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12-month low of $23.58 and a 12-month high of $28.75. The firm has a market capitalization of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. The firm’s 50 day simple moving average is $25.30 and its two-hundred day simple moving average is $26.25.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the company posted $0.78 earnings per share. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.